Cortexyme

General Information
Business:

 

We are a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what we believe to be a key underlying cause of Alzheimer’s and other degenerative diseases. Our approach is based on the seminal discovery of the presence of Porphyromonas gingivalis, or P. gingivalis, and its secreted toxic virulence factor proteases, called gingipains, in the brains of greater than 90% of more than 100 Alzheimer’s patients observed across multiple studies to date. Additionally, we have observed that P. gingivalis infection causes Alzheimer’s pathology in animal models, and these effects have been successfully treated with a gingipain inhibitor in preclinical studies.

Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
Employees: 19
Founded: 2012
Contact Information
Address 269 East Grand Avenue, South San Francisco, CA 94080, US
Phone Number (415) 910-5717
Web Address http://www.cortexyme.com
View Prospectus: Cortexyme
Financial Information
Market Cap $442.2mil
Revenues $0 mil (last 12 months)
Net Income $-12.5 mil (last 12 months)
IPO Profile
Symbol CRTX
Exchange NASDAQ
Shares (millions): 4.4
Price range $17.00 - $17.00
Est. $ Volume $75.0 mil
Manager / Joint Managers BofA Merrill Lynch/ Credit Suisse
CO-Managers Canaccord Genuity/ JMP Securities
Expected To Trade: 5/9/2019
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change